ImmunityBio is a clinical-stage biotechnology company developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. Co.'s platforms include: antibody cytokine fusion proteins, which include Anktiva, a class of biopharmaceuticals that enhance the therapeutic potential of cytokines, and promote lymphocyte infiltration at a site of disease, improving immune response; and DNA, RNA, and recombinant protein vaccine technologies, which are for infectious diseases to target viruses, including SARS-CoV-2, and for oncology to deliver common tumor-associated antigens, and neoepitopes (expressed only by cancer cells).